Alexandria Real Estate-backed Acrivon has filed to go public while H2 Green Steel increased its corporate-backed series B round to $255m.

eye

Public markets

Acrivon Therapeutics, the US-based oncology therapy developer backed by life sciences real estate investment trust Alexandria Real Estate Equities, has filed for an initial public offering on the Nasdaq Global Market. Its overall funding stood at over $115m as of November 2021.

Reverse merger

Oculis, the Switzerland-based eyesight treatment developer backed by pharmaceutical firm Novartis and property developer Nan Fung, is…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Edison Fu

Edison Fu is a reporter and Asia liaison at Global Corporate Venturing.
Email LinkedIn